tradingkey.logo

默沙东

MRK
106.850USD
+0.400+0.38%
收盘 12/26, 16:00美东报价延迟15分钟
265.77B总市值
14.10市盈率 TTM

默沙东

106.850
+0.400+0.38%

关于 默沙东 公司

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

默沙东简介

公司代码MRK
公司名称Merck & Co Inc
上市日期Feb 06, 2077
CEODavis (Robert M)
员工数量75000
证券类型Ordinary Share
年结日Feb 06
公司地址126 East Lincoln Avenue
城市RAHWAY
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编07065
电话19087404000
网址https://www.merck.com/
公司代码MRK
上市日期Feb 06, 2077
CEODavis (Robert M)

默沙东公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
其他
4.47B
28.27%
地区USD
名称
营收
占比
United States
8.84B
55.90%
Europe, Middle East and Africa
3.66B
23.15%
Latin America
859.00M
5.43%
Asia Pacific (Other than China and Japan)
785.00M
4.97%
Japan
626.00M
3.96%
其他
1.04B
6.59%
业务
地区
业务USD
名称
营收
占比
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
其他
4.47B
28.27%

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
其他
74.00%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
其他
74.00%
股东类型
持股股东
占比
Investment Advisor
42.31%
Investment Advisor/Hedge Fund
26.78%
Research Firm
3.18%
Pension Fund
2.51%
Bank and Trust
2.21%
Sovereign Wealth Fund
1.55%
Hedge Fund
1.06%
Insurance Company
0.69%
Family Office
0.13%
其他
19.59%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
5358
2.02B
81.35%
-45.75M
2025Q2
5398
2.02B
80.82%
-16.42M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
251.75M
10.08%
+356.59K
+0.14%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
142.78M
5.72%
-4.51M
-3.06%
Jun 30, 2025
State Street Investment Management (US)
118.49M
4.74%
-2.04M
-1.69%
Jun 30, 2025
Wellington Management Company, LLP
76.86M
3.08%
-4.81M
-5.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
58.95M
2.36%
-704.59K
-1.18%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
53.87M
2.16%
+4.64M
+9.42%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
36.11M
1.45%
+1.13M
+3.23%
Jun 30, 2025
Fidelity Management & Research Company LLC
28.48M
1.14%
+229.47K
+0.81%
Jun 30, 2025
Fisher Investments
25.01M
1%
+567.90K
+2.32%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
22.79M
0.91%
+764.14K
+3.47%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
VanEck Pharmaceutical ETF
16.09%
FT Vest DJIA Dogs 10 Target Income ETF
10.79%
First Trust NASDAQ Pharmaceuticals ETF
7.94%
Invesco Dow Jones Industrial Average Dividend ETF
6.94%
First Trust Morningstar Dividend Leaders Index Fund
5.39%
Coastal Compass 100 ETF
5.13%
Invesco Pharmaceuticals ETF
4.96%
VanEck Morningstar Wide Moat Value ETF
4.73%
Vaneck Durable High Dividend ETF
4.65%
Franklin Income Focus ETF
4.56%
查看更多
VanEck Pharmaceutical ETF
占比16.09%
FT Vest DJIA Dogs 10 Target Income ETF
占比10.79%
First Trust NASDAQ Pharmaceuticals ETF
占比7.94%
Invesco Dow Jones Industrial Average Dividend ETF
占比6.94%
First Trust Morningstar Dividend Leaders Index Fund
占比5.39%
Coastal Compass 100 ETF
占比5.13%
Invesco Pharmaceuticals ETF
占比4.96%
VanEck Morningstar Wide Moat Value ETF
占比4.73%
Vaneck Durable High Dividend ETF
占比4.65%
Franklin Income Focus ETF
占比4.56%

分红派息

近5年累计派现 35.12B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Nov 18, 2025
MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Jan 08, 2026 going ex on Dec 15, 2025
Dec 15, 2025
Jan 08, 2026
Dec 15, 2025
Jul 22, 2025
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Oct 07, 2025 going ex on Sep 15, 2025
Sep 15, 2025
Oct 07, 2025
Sep 15, 2025
May 27, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Jul 08, 2025 going ex on Jun 16, 2025
Jun 16, 2025
Jul 08, 2025
Jun 16, 2025
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
查看更多

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

默沙东的前五大股东是谁?

默沙东 的前五大股东如下:
The Vanguard Group, Inc.持有股份:251.75M,占总股份比例:10.08%。
BlackRock Institutional Trust Company, N.A.持有股份:142.78M,占总股份比例:5.72%。
State Street Investment Management (US)持有股份:118.49M,占总股份比例:4.74%。
Wellington Management Company, LLP持有股份:76.86M,占总股份比例:3.08%。
Geode Capital Management, L.L.C.持有股份:58.95M,占总股份比例:2.36%。

默沙东的前三大股东类型是什么?

默沙东 的前三大股东类型分别是:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)

有多少机构持有默沙东(MRK)的股份?

截至2025Q3,共有5358家机构持有默沙东的股份,合计持有的股份价值约为2.02B,占公司总股份的81.35%。与2025Q2相比,机构持股有所增加,增幅为0.53%。

哪个业务部门对默沙东的收入贡献最大?

在FY2025Q2,Oncology-Keytruda业务部门对默沙东的收入贡献最大,创收7.96B,占总收入的50.34%。
KeyAI